AOD-9604 + MOTS-c

1. AOD-9604 — Adipocyte lipolysis and reduced fat storage. AOD-9604 is a modified fragment of the C-terminal region of human growth hormone (residues 176–191) with an added N-terminal tyrosine for stability. In preclinical models it stimulates lipolysis (fat breakdown) and inhibits lipogenesis (new fat storage), in part by raising β3-adrenergic receptor expression in adipose tissue back toward lean-equivalent levels and by activating hormone-sensitive lipase. Critically, it does not bind the growth-hormone receptor, does not raise IGF-1, and does not impair glucose metabolism — distinguishing it from full-length hGH. [1][2]
2. MOTS-c — AMPK activation and fat oxidation. MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA. Its primary target is skeletal muscle, where it inhibits the folate cycle and de novo purine biosynthesis, causing AICAR to accumulate, which in turn activates AMPK — the cell's master energy sensor. AMPK activation shifts cells toward catabolism: increased glucose uptake, increased fatty-acid oxidation, and suppressed lipogenesis. In mice, MOTS-c prevented diet-induced obesity and insulin resistance. [3]
3. Complementary, non-overlapping pathways. AOD-9604 acts on adipocyte signaling (β3-AR / hormone-sensitive lipase); MOTS-c acts on the AMPK energy-sensing axis. The combination theory is that AOD-9604 increases the supply of free fatty acids while MOTS-c improves the mitochondrial capacity to burn them and improves insulin sensitivity in parallel — additive rather than redundant in principle.
4. A non-GH, non-GLP-1 profile. Neither peptide acts through the GH receptor or the GLP-1 receptor. Because neither raises IGF-1 or, for AOD-9604, affects blood glucose, the pairing is studied as a fat-metabolism approach that sidesteps the GH/IGF-1 axis pressure of secretagogue stacks and the appetite-axis mechanism of GLP-1 drugs.

The important caveat: every point above is grounded in single-compound research. There is no published study of the combination, and the strongest human signal for either peptide is limited (see Limitations).

1. Fat-loss / body-composition research. The headline use case: AOD-9604's lipolytic signaling combined with MOTS-c's fat-oxidation and metabolic-flexibility effects. Preclinical AOD-9604 work shows reduced body weight and fat in obese models; MOTS-c reduces visceral fat and hepatic steatosis in mice.
2. Insulin-sensitivity and metabolic-health research. Driven primarily by the MOTS-c arm, which improves insulin sensitivity and glucose handling via AMPK and reversed age-dependent muscle insulin resistance in mice.
3. Visceral / stubborn-fat research. Both peptides are studied in the context of abdominal and visceral adipose depots in animal models.
4. Exercise-metabolism and metabolic-aging research. MOTS-c is an exercise-induced “mitochondrial hormone,” and circulating levels are lower in obesity and type 2 diabetes — making the stack relevant to exercise-mimetic and metabolic-aging study designs.

For appetite-driven weight research, GLP-1 compounds such as Semaglutide, Tirzepatide, and Retatrutide act through a different (incretin) mechanism and have far stronger human outcome data; some protocols pair them with this metabolic stack (see Stacks).

Both peptides are administered by subcutaneous injection. Because there is no standardized blend, the two are usually dosed separately even when bought together. The figures below are commonly reported research protocols, not validated clinical doses — and no controlled combination protocol exists.

Commonly reported research protocol:

1. AOD-9604. ~300 mcg subcutaneously per day, often dosed in the morning or fasted. Supplied as a lyophilized vial (commonly 2–5 mg total), reconstituted with bacteriostatic water.
2. MOTS-c. ~5–10 mg per week, frequently split across 2–3 subcutaneous doses. Supplied as a lyophilized vial (commonly 10 mg total).
3. Cycle length. 8–12 weeks active, with a break before re-cycling.
4. Reconstitution. Bacteriostatic water; use the dosage calculator to convert mg/mcg to syringe units and plan reconstitution.

Need to calculate a dose? Convert mg/mcg to syringe units and plan reconstitution with the dosage calculator →.

Neither component is FDA-approved as an injectable; compounded preparations vary widely in quality, and third-party HPLC testing is essential.

• No combination studies exist. Every claim rests on each peptide's separate literature plus mechanistic reasoning about complementarity.
• AOD-9604's pivotal human trial failed. Despite strong preclinical fat-loss signals and an excellent safety record across roughly six clinical trials (~900 participants), the pivotal Phase IIb study did not show clinically meaningful weight loss versus placebo, and commercial development was terminated in 2007. AOD-9604 is not FDA-approved for obesity. (Australia's TGA has separately approved an AOD-9604 preparation for a non-obesity, intra-articular indication.)
• MOTS-c human efficacy data is observational, not interventional. The strong findings (prevented diet-induced obesity, improved insulin resistance) are from mouse studies. In humans, lower circulating MOTS-c is associated with obesity and type 2 diabetes, but there are no controlled human trials showing that administering MOTS-c produces fat loss.
• Regulatory and quality status. Neither peptide is FDA-approved as an injectable; both are sold as “research peptides,” and compounded quality varies dramatically. Third-party HPLC testing is strongly recommended to verify identity and purity.

The honest summary: mechanistically coherent, well-tolerated in the case of AOD-9604, but clinically unproven as a combination — and the lipolytic arm has a notable human-efficacy failure on record.